Antihemophilic factor, PEGylated, Recombinant Human coagulation factor VIII/F8

Specification

• Cat#: THP-0050
• Product Name: Antihemophilic factor, PEGylated, Recombinant Human coagulation factor VIII/F8
• Cas No: 1628187-15-4
• Description: The product is a recombinant full-length human coagulation factor VIII (2,332 amino acids with a molecular weight (MW) of 280 kDa) covalently conjugated with at least one molecule of polyethylene glycol (MW 20 kDa). It is purified from the culture medium using several chromatography columns. The purification process includes immunoaffinity chromatography, in which a monoclonal antibody directed against factor VIII is promoted to selectively isolate the factor VIII from the medium. The production process includes a viral inactivation solvent-detergent treatment step. The product molecule is then covalently conjugated with the polyethylene glycol, which primarily targets lysine residues.
• Sequences: Full Length F8
• Species: Human
• Molecular Weight: Not Available
• Formula: Not Available
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Biological Activity: 3000U
• Application: For the treatment of hemophilia A (congenital factor VIII deficiency).This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease.

Pharmaceutical Information

• Pharmaceutical Application: Antihemophilic Factor (Recombinant), PEGylated
• Targets: Target 1. von Willebrand factor; Target 2. Coagulation factor IX; Target 3. Coagulation factor X; Enzyme 1. von Willebrand factor; Enzyme 2. Phosphatidylcholine transfer protein